

Patent Application
Attorney Docket No. PC11026AJAK

1645

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Hon. Commissioner for Patents, Washington, D.C. 20231 on this 21st day of February, 2002.

#3 attachment

By

Deanna L. Miller
(Signature of person mailing)
Deanna L. Miller

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Stephanie K. Hall, et al :

APPLICATION NO.: 10/032,242

: Examiner: To be assigned

FILING DATE: December 21, 2001

: Group Art Unit: 1645

TITLE: Methods and Reagents for Detecting Increased
Risk of Developing An Inflammatory Disorder :

RECEIVED

MAR 05 2002

Hon. Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900


Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820, which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).




Patent Application
Attorney Docket No. PC11026AJAK

A prompt and favorable response is earnestly solicited.


Date: **FEBRUARY 21, 2002**

Respectfully submitted,



Jennifer A. Kispert
Attorney for Applicant(s)
Reg. No. 40,049

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5747



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC11026AJAK	SERIAL NO. 10/032,242
	APPLICANT Stephanie K. Hall, et al	
	FILING DATE December 21, 2001	GROUP 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

RECEIVED

MAR 05 2002


FOREIGN PATENT DOCUMENTS

TECH CENTER 1600/2900

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		A. C. Issekutz, et al., Immunology, Volume 88, pages 569-576, 1996, "Treatment of Established Adjuvant Arthritis in Rats With Monoclonal Antibody to CD18 and Very Late Activation Antigen-4 Integrins Suppresses Neutrophil and T-lymphocyte Migration to the Joints and Improves Clinical Disease".
		M. P. Bevilacqua, et al., Science, Vol. 243, pages 1160-1165, March 3, 1989, "Endothelial Leukocyte Adhesion Molecule 1: An Inducible Receptor for Neutrophils Related to Complement Regulatory Proteins and Lectins".
		Z. Guan, et al., The Journal of Biological Chemistry, Vol. 273, No. 44, Issue of October 30, pages 28670-28676, 1998, "Interleukin-1 β -induced Cyclooxygenase-2 Expression Requires Activation of Both c-Jun NH ₂ -terminal Kinase and p38 MAPK Signal Pathways in Rat Renal Mesangial Cells".
		C. R. Flannery, et al., Matrix Biology, Volume 18, pages 225-237, 1999, "Effects of Culture Conditions and Exposure to Catabolic Stimulators (IL-1 and Retinoic Acid) on the Expression of Matrix Metalloproteinases (MMPs) and Disintegrin Metalloproteinases (ADAMs) by Articular Cartilage Chondrocytes".
		E. M. El-Omar, et al., Nature, Vol. 404, pages 398-402, March 23, 2000, "Interleukin-1 Polymorphisms Associated With Increased Risk of Gastric Cancer".
		F. Pociot, et al., European Journal of Clinical Investigation, Vol. 22, pages 396-402, 1992, "A TaqI Polymorphism in the Human Interleukin-1 β secretion <i>in vitro</i> ".
		C. Zheng, et al., British Journal of Haematology, Volume 109, pages 39-45, 2000, "Interleukin 6, Tumour Necrosis Factor α , Interleukin 1 β and Interleukin 1 Receptor Antagonist Promoter or Coding Gene Polymorphisms in Multiple Myeloma".
		M. Takamatsu, et al., The American Journal of Gastroenterology, Vol. 95, No. 5, pages 1305-1311, 2000, "Genetic Polymorphisms of Interleukin-1 β in Association With the Development of Alcoholic Liver Disease in Japanese Patients".
		D. Huang, et al., Journal of Neuroimmunology, Vol. 81, pages 76-81, 1998, "Polymorphisms in IL-1 β and IL-1 Receptor Antagonist Genes are Associated With Myasthenia Gravis".
		S. Santtila, et al., Scand. J. Immunol., Volume 47, pages 195-198, 1998, "Presence of the IL-1RA Allele 2 (IL1RN*2) is Associated With Enhanced IL-1 β Production <i>In Vitro</i> ".
		U. T. Hacker, et al., European Journal of Clinical Investigation, Volume 28, pages 214-219, 1998, "Inflammatory Bowel Disease: No Association Between Allele Combinations of the Interleukin (IL) 1 β and IL-1 Receptor Antagonist Gene Polymorphisms".
		S. Cookson, et al., Vol. 30, No. 4, pages 851-856, 1999, "Frequency and Nature of Cytokine Gene Polymorphisms in Type 1 Autoimmune Hepatitis".
		E. Sharma, et al., The Journal of Biological Chemistry, Vol. 270, No. 1, Issue of January 6, pages 49-53, 1995, "A Neuronal Protein Tyrosine Phosphatase Induced by Nerve Growth Factor".



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC11026AJAK	SERIAL NO. 10/032,242
			APPLICANT Stephanie K. Hall, et al	
			FILING DATE December 21, 2001	GROUP 1645
			M. Ogata, et al., The Journal of Biological Chemistry, Vol. 270, No. 5, Issue of February 3, pp. 2337-2343, 1995, cDNA Cloning and Characterization of a Novel Receptor-type Protein Tyrosine Phosphatase Expressed Predominantly in the Brain*."	
			W. Hendriks, et al., Biochem. J., Volume 305, pages 499-504, 1995, A Novel Receptor-Type Protein Tyrosine Phosphatase With a Single Catalytic Domain is Specifically Expressed in Mouse Brain."	
			G. Daum, et al., Analytical Biochemistry, Volume 211, pages 50-54, 1993, "A General Peptide Substrate for Protein Tyrosine Phosphatases".	
			K. W. Harder, et al., Biochem. J., Volume 298, pages 395-401, 1994, "Characterization and Kinetic Analysis of the Intracellular Domain of Human Protein Tyrosine Phosphatase β (HPTP β) Using Synthetic Phosphopeptides".	
EXAMINER			DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

RECEIVED
MAR 05 2002
TECH CENTER 1600/2900